Literature DB >> 9588527

Long-term outcomes of pediatric moyamoya disease monitored to adulthood.

T Imaizumi1, K Hayashi, K Saito, M Osawa, Y Fukuyama.   

Abstract

The long-term outcomes of 25 patients with childhood moyamoya disease (18 with the transient ischemic attack [TIA] type and seven with the non-TIA type), who were monitored to adulthood (older than 20 years of age), were evaluated in terms of residual clinical symptoms, intellectual development, and activities of daily living. Surgical treatment was performed in ten patients, encephaloduroarteriosynangiosis in nine, and superficial temporal artery to middle cerebral artery anastomosis plus encephalomyosynangiosis in one. Only seven with the TIA type (three surgically and four medically treated) demonstrated good activities of daily living without TIA or headache and normal IQ. Two patients with the TIA type and three with the non-TIA type demonstrated poor outcomes. Three of these patients with poor outcomes had renal artery stenosis. Surgery was effective in nine. Since the long-term outcomes of patients with childhood moyamoya disease are generally poor, surgical treatment is believed to be an effective procedure for preventing the progression of clinical symptoms.

Entities:  

Mesh:

Year:  1998        PMID: 9588527     DOI: 10.1016/s0887-8994(97)00209-9

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  30 in total

1.  Moyamoya disease with renal artery and external iliac artery stenosis.

Authors:  Javed Ahmed; Uma S Ali
Journal:  Indian J Pediatr       Date:  2010-10-01       Impact factor: 1.967

2.  Headache attack followed by rapid disease progression in pediatric moyamoya disease--how should we manage it?

Authors:  Sandra Vuignier; Naoki Akioka; Hideo Hamada; Daina Kashiwazaki; Satoshi Kuroda
Journal:  Childs Nerv Syst       Date:  2014-04-01       Impact factor: 1.475

3.  Unilateral (probable) moyamoya disease: long-term follow-up of seven cases.

Authors:  Ho Jun Seol; Kyu-Chang Wang; Seung-Ki Kim; Chang Sub Lee; Dong Soo Lee; In-One Kim; Byung-Kyu Cho
Journal:  Childs Nerv Syst       Date:  2005-10-12       Impact factor: 1.475

4.  Posterior cerebral artery involvement in moyamoya disease: initial infarction and angle between PCA and basilar artery.

Authors:  Ji Yeoun Lee; Seung-Ki Kim; Jung-Eun Cheon; Jung Won Choi; Ji Hoon Phi; In-One Kim; Byung-Kyu Cho; Kyu-Chang Wang
Journal:  Childs Nerv Syst       Date:  2013-05-08       Impact factor: 1.475

5.  Treatment course and outcomes after revascularization surgery for moyamoya disease in adults.

Authors:  Amanda Kahn; Gurmeen Kaur; Laura Stein; Stanley Tuhrim; Mandip S Dhamoon
Journal:  J Neurol       Date:  2018-09-08       Impact factor: 4.849

6.  Delayed posterior circulation insufficiency in pediatric moyamoya disease.

Authors:  Ji Yeoun Lee; Young-Hun Choi; Jung-Eun Cheon; Jin Chul Paeng; Hye Won Ryu; Ki Joong Kim; Ji Hoon Phi; Kyu-Chang Wang; Byung-Kyu Cho; Jong-Hee Chae; Seung-Ki Kim
Journal:  J Neurol       Date:  2014-09-12       Impact factor: 4.849

7.  Surgical management of moyamoya syndrome.

Authors:  Edward R Smith; R Michael Scott
Journal:  Skull Base       Date:  2005-02

8.  Moyamoya disease in adults: the role of cerebral revascularization.

Authors:  Gregory J Zipfel; Douglas J Fox; Dennis J Rivet
Journal:  Skull Base       Date:  2005-02

9.  CT perfusion assessment of Moyamoya syndrome before and after direct revascularization (superficial temporal artery to middle cerebral artery bypass).

Authors:  Yueqin Chen; Wenjian Xu; Xiang Guo; Zhitao Shi; Zhanguo Sun; Lingyun Gao; Feng Jin; Jiehuan Wang; Weijian Chen; Yunjun Yang
Journal:  Eur Radiol       Date:  2015-05-01       Impact factor: 5.315

10.  Early-onset stroke with moyamoya-like syndrome and extraneurological signs: a first reported paediatric series.

Authors:  Bruno Law-Ye; Guillaume Saliou; Frédérique Toulgoat; Marc Tardieu; Kumaran Deiva; Catherine Adamsbaum; Béatrice Husson
Journal:  Eur Radiol       Date:  2015-11-28       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.